DORZOLAMIDE-TIMOLOL SOLUTION

देश: कनाडा

भाषा: अंग्रेज़ी

स्रोत: Health Canada

इसे खरीदें

सक्रिय संघटक:

TIMOLOL (TIMOLOL MALEATE); DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE)

थमां उपलब्ध:

MICRO LABS LIMITED

ए.टी.सी कोड:

S01ED51

INN (इंटरनेशनल नाम):

TIMOLOL, COMBINATIONS

डोज़:

5MG; 20MG

फार्मास्यूटिकल फॉर्म:

SOLUTION

रचना:

TIMOLOL (TIMOLOL MALEATE) 5MG; DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) 20MG

प्रशासन का मार्ग:

OPHTHALMIC

पैकेज में यूनिट:

100

प्रिस्क्रिप्शन प्रकार:

Prescription

उत्पाद समीक्षा:

Active ingredient group (AIG) number: 0237301001; AHFS:

प्राधिकरण का दर्जा:

APPROVED

प्राधिकरण की तारीख:

2022-06-23

उत्पाद विशेषताएं

                                _Page 1 of 37_
_DORZOLAMIDE-TIMOLOL (Dorzolamide Hydrochloride and Timolol Maleate
Ophthalmic Solution)_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
DORZOLAMIDE-TIMOLOL
Dorzolamide
Hydrochloride and Timolol Maleate Ophthalmic Solution
Ophthalmic Solution, 20 mg / mL dorzolamide (as dorzolamide
hydrochloride) and 5 mg / mL
timolol (as timolol maleate)
USP
Elevated Intraocular Pressure Therapy
Topical Carbonic Anhydrase Inhibitor and Topical Beta-Adrenergic
Blocking Agent
Manufactured by:
Date of Initial Approval:
Micro Labs Limited
June 16, 2022
Bangalore– 560001
INDIA
Canadian Importer/Distributor:
13187811
Canada Inc.
Mississauga, ON L4Z 1S1
Submission Control Number: 250138
_Page 2 of 37_
_DORZOLAMIDE-TIMOLOL (Dorzolamide Hydrochloride and Timolol Maleate
Ophthalmic Solution)_
RECENT MAJOR LABEL CHANGES
Not applicable.
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL
CHANGES.............................................................................................
2
TABLE OF CONTENTS
...............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................................
4
1
INDICATIONS
....................................................................................................
4
1.1
Pediatrics
................................................................................................
4
1.2
Geriatrics
................................................................................................
4
2
CONTRAINDICATIONS.......................................................................................
4
4
DOSAGE AND ADMINISTRATION
......................................................................
5
4.1
Dosing Considerations
.............................................................................
5
4.2
Recommended Dose and Dosage Adjustment
.............
                                
                                पूरा दस्तावेज़ पढ़ें
                                
                            

अन्य भाषाओं में दस्तावेज़

उत्पाद विशेषताएं उत्पाद विशेषताएं फ़्रेंच 16-06-2022

इस उत्पाद से संबंधित अलर्ट देखें

दस्तावेज़ इतिहास देखें